Oxaliplatin
Treatment Eloxatin
 
At what stage is this treatment used?

  • Adjuvant treatment of stage III (Dukes C) colon cancer after complete resection of primary tumour.
  • Treatment of advanced (metastatic) colorectal cancer.
 
Is this drug available via the Pharmaceutical Benefits Scheme (PBS) as a subsidised treatment?

  • Oxaliplatin in combination with 5-FU and folinic acid (FOLFOX) is PBS-subsidised as a treatment option for the adjuvant treatment of patients with stage III (Dukes C) colon cancer following complete resection of the primary tumour.
  • Oxaliplatin in combination with 5-FU and folinic acid (FOLFOX) or capecitabine (XELOX) is PBS-subsidised as a treatment option for advacned (metastatic) colorectal cancer in patients with a WHO performance status of 2 or less.
  • Oxaliplatin is not PBS-subsidised for the treatment of patients with stage II (Dukes B) colon cancer.  Oxaliplatin is not PBS-subsidised for the adjuvant treatment of patients with rectal cancer.
  • Capecitabine in combination with oxaliplatin (XELOX) is listed as a PBS-subsidised treatment option for the adjuvant treatment of stage III (Dukes C) colon cancer, which allows Xeloda to be reimbursed as both monotherapy and as part of the XELOX combination.

Download the Consumer Medicine Information (CMI) for Eloxatin.
  
Banner Bowel Cancer Australia Helpline
Bowel Cancer Australia Bowel Cancer App